UBS downgraded GE HealthCare to Sell from Neutral with a price target of $66, down from $86. Soft orders, tough compares and a lack of prices rises puts UBS estimates below the 2024 consensus, the analyst tells investors in a research note. The form is more cautious on GE HealthCare’s Imaging margin approach and sees margin disappointments ahead.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GEHC:
- GE HealthCare announces new version of Digital Expert Access, deal with IONIC
- GE HealthCare, BAMF Health collaborate for Theranostics solutions
- GE HealthCare, Masimo team to bring SE Pulse Oximetry to mobile platform
- GE Healthcare (NASDAQ:GEHC) Surges After New Plans Emerge
- Early notable gainers among liquid option names on October 31st